Frontiers in Oncology (May 2023)

The key role of microRNA-766 in the cancer development

  • Jitendra Gupta,
  • Hussein Riyadh Abdul Kareem Al-Hetty,
  • Murtadha Sh. Aswood,
  • Abduladheem Turki Jalil,
  • Maha Dhurgham Azeez,
  • Zafar Aminov,
  • Zafar Aminov,
  • Fahad Alsaikhan,
  • Andrés Alexis Ramírez-Coronel,
  • Andrés Alexis Ramírez-Coronel,
  • Andrés Alexis Ramírez-Coronel,
  • Pushpamala Ramaiah,
  • Bagher Farhood

DOI
https://doi.org/10.3389/fonc.2023.1173827
Journal volume & issue
Vol. 13

Abstract

Read online

Cancer is caused by defects in coding and non-coding RNAs. In addition, duplicated biological pathways diminish the efficacy of mono target cancer drugs. MicroRNAs (miRNAs) are short, endogenous, non-coding RNAs that regulate many target genes and play a crucial role in physiological processes such as cell division, differentiation, cell cycle, proliferation, and apoptosis, which are frequently disrupted in diseases such as cancer. MiR-766, one of the most adaptable and highly conserved microRNAs, is notably overexpressed in several diseases, including malignant tumors. Variations in miR-766 expression are linked to various pathological and physiological processes. Additionally, miR-766 promotes therapeutic resistance pathways in various types of tumors. Here, we present and discuss evidence implicating miR-766 in the development of cancer and treatment resistance. In addition, we discuss the potential applications of miR-766 as a therapeutic cancer target, diagnostic biomarker, and prognostic indicator. This may shed light on the development of novel therapeutic strategies for cancer therapy.

Keywords